Bird & Bird advises Precision Medicine Group on the acquisition of Epiontis

09 October 2017

Bird & Bird LLP advises Precision Medicine Group, a scientific services company helping life science innovators develop medical products, on the acquisition of all shares in Epiontis GmbH, a leading immune monitoring and epigenetic technology service provider based in Berlin.

The acquisition will allow Precision for Medicine to expand on its immune monitoring capabilities with Epiontis’s epigenetic technology, and strengthen its global footprint in the rapidly expanding precision medicine sector. 

The Bird & Bird team advised Precision for Medicine on the due diligence, signing and closing of the transaction, including IP patent due diligence and regulatory advice regarding  the life sciences aspects of the deal. 

Stefan Münch (Corporate/M&A, Munich) led the transaction on the German law aspects, assisted by counsel Stephan Kübler and associates Michael Gassner and Benedikt Weiss (both Corporate/M&A, Munich), partner Ralph Panzer and associate Julia Gottinger (both Employment, Munich), counsel Gerrit Wiedow (Employment, Hamburg), partners Michael Alt, Christopher Maierhöfer and associate Marie-Theres Schmid (all Patents, Munich), partner Markus Körner and counsel Thomas Urband (both Trademarks, Munich), partner Alexander Csaki and associate Clarissa Junge-Gierse (both Life Sciences/Regulatory, Munich) and partner Michael Jünemann (Finance, Frankfurt). Bird & Bird London partner Ali Ramadan and associate Hannah Fletcher (both Corporate/M&A, London) also assisted on the UK law issues. Legal in-house advisors were General Counsel John Mariano and Senior Counsel Rita Khoobchandani.